EYLEA

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug EYLEA contains one active pharmaceutical ingredient (API):

1	Aflibercept UNII 15C2VL427D - AFLIBERCEPT
	Aflibercept, also known as VEGF TRAP in the scientific literature, is a recombinant fusion protein consisting of VEGF-binding portions from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of the human IgG1. Aflibercept blocks the activation of VEGF receptors and the proliferation of endothelial cells, thereby inhibiting the growth of new vessels that supply tumours with oxygen and nutrients.
	Read more about Aflibercept

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
EYLEA 40 mg/ml Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)
EYLEA 114.3 mg/ml Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)
EYLEA 40 mg/mL Solution for injection in pre-filled syringe	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01LA05	Aflibercept	S Sensory organs → S01 Ophthalmologicals → S01L Ocular vascular disorder agents → S01LA Antineovascularisation agents
Discover more medicines within S01LA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10505X, 11991D, 12131L, 12132M, 12141B, 12152N, 12153P, 2168D
CA	Health Products and Food Branch	02415992, 02505355
EE	Ravimiamet	1601457, 1601468
ES	Centro de información online de medicamentos de la AEMPS	112797001, 112797002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	145450, 532599
FR	Base de données publique des médicaments	68795701, 69613703
GB	Medicines & Healthcare Products Regulatory Agency	216745, 381939
HK	Department of Health Drug Office	61971
IL	מִשְׂרַד הַבְּרִיאוּת	7384, 9081
JP	医薬品医療機器総合機構	1319405A1027, 1319405G1020
LT	Valstybinė vaistų kontrolės tarnyba	1068441, 1093378
NL	Z-Index G-Standaard, PRK	103756
NZ	Medicines and Medical Devices Safety Authority	15565
PL	Rejestru Produktów Leczniczych	100291098
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W63881001, W68189001
SG	Health Sciences Authority	14345P, 14380P
TN	Direction de la Pharmacie et du Médicament	12853081H
TR	İlaç ve Tıbbi Cihaz Kurumu	8699546770052, 8699546959358
US	FDA, National Drug Code	61755-005
ZA	Health Products Regulatory Authority	46/15.4/0841